This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Branded Generics Market

Market Insights on Branded Generics covering sales outlook, demand forecast & up-to-date key trends

Branded Generics Market by Therapeutic Application (Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Analgesics and Anti-inflammatory), Drug Class (Alkylating Agents, Antimetabolites, Anti-Hypertensive), Formulation Type, End User & Region - Forecast to 2021 - 2031

Branded Generics Market Snapshot

[280 Pages Report] Branded Generics Market will register a year-on-year growth of 4.9% in 2021, reaching a valuation of 283.2 Bn, ESOMAR-certified market research firm Future Market Insights (FMI) has forecasted in its latest market research.

On account of the growing popularity, the Branded Generics Market is poised to expand at a CAGR of 5.8% between 2021 and 2031. The top players are expected to hold nearly 20%-25% share in the overall market in 2021.

Asia Pacific Excluding Japan (APEJ) continues to dominate the global Branded Generics Market due to the increasing rate of branded generics uptake by large-scale pharmacy chains in the emerging economies

Customize this Report

Let us know your requirement to get
100% FREE customization

Branded Generics Market Survey - Key Points Covered

  • Branded Generics Market estimates and forecast 2021-2031
  • Key drivers and restraints impacting Branded Generics Market growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competition Mapping and Benchmarking
  • Brand share and Branded Generics Market Share Analysis
  • Key Product Innovations and Regulatory Climate
  • COVID-19 Impact on Branded Generics Market and how to Navigate
  • Recommendation on Key Winning Strategies

Branded Generics Market Historic Sales Compared to 2021-2031 Forecast Outlook

The Branded Generics Market is set to register a CAGR of 5.8% between 2021 and 2031 in comparison to 6.5% CAGR registered from 2016 to 2020.

With the skyrocketing healthcare costs and the rising need for quality generic drugs, the interest in branded generics has increased across the world. Drug patent expiration is mainly driving the branded generics market.

Consumer choice is vital in accelerating the growth of branded generic market. People tend to choose the best products they can afford. Brands command a premium trust, consistent quality and delivery of a promise.

Branded Generics Market Download Report Brochure

A Branded Generic is a generic drug which has gone through Abbreviated New Drug Application (ANDA) process. Increasing prevalence of chronic ailments will positively impact the demand for branded generics.

Changing lifestyle has led to the higher incidence of cardiovascular diseases and other ailments such as diabetes and hypertension. As a result, there has been a gradual surge in the sales of anti-hypersensitive branded generics.

According to World Health Organization (WHO) around 17.9 million people die each year from cardiovascular diseases (CVDs) around the world. To counter these diseases and minimize the overall cost of treatment, patients are shifting to branded generics.

Will Developing Economics Emerge as Lucrative Pockets for Branded Generics Sales?

The demand for Branded Generics is increasing in low- and middle-income countries. They are far more common in countries like India, China, Brazil, and Mexico, serving middle- and lower-income consumers where other options are few.

Emerging markets are home to more than 70% of the world's population. These markets can be tricky for pharmaceutical players that are more comfortable operating in developed market environments.

Branded generic companies are employing various strategies to penetrate emerging markets. They are indulging in enhancing their contracting capabilities and improving their portfolio marketing.

Various organizations and companies are investing to expand their footprint in underdeveloped, which will aid the overall expansion of the Branded Generics Market. For instance, in November 2020, CDC Group, Development Partners International (DPI), and the European Bank for Reconstruction and Development (EBRD) joined forces to create a new US$ 750 Mn platform for delivering affordable treatments across Africa, by combining Egyptian Pharmaceuticals manufacturer with Indian generic drugs company.

First, of its kind, Pan-Africa Pharma platform will generate significant cost savings for healthcare providers across Africa and broaden the range of therapeutics available in underserved markets.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Branded Generics Market - Country-wise Insights

How Will China Retain the Dominance of Leading Branded Generics Market?

The pharmaceutical industry in China is driven by low price and high popularity of branded generic drugs. China has adopted a fast-track approach in its drug evaluation and approval system allowing more new domestic drugs, innovative drugs and imported drugs to hit the market.

The market in China is highly competitive with government controlling the drug approval and drug development. Growing popularity of generic and branded generics with their cost-effective features is driving the market in the country.

According to the work plan jointly issued by 12 government departments including National Health Commission, China will publish and update the list of generic drugs at the end of every year.

In 2018, China released its first list of marketed medicine, with 131 types of medicine in 203 specifications, according to the China Food and Drug Administration (CFDA). The list contains both generic and branded medicines, and specifies reference preparations, which offer research standards for generic medicines.

With the expanding pharmaceutical industry, China is expected to offer plethora of opportunities for the manufacturers of branded generics.

How is the Demand for Branded Generics Faring in India?

India is one of the biggest exporters of generic medicines to various countries such as the U.S., Europe and Africa. Brand generic drug makers are able to both develop and sell the generic medications at a much lower cost without compromising the quality of the product.

According to India Brand Equity foundation, the pharmaceutical sector in India supplies over 50% of global demand for various vaccines, 40% of generic demand in the U.S. and 25% of all medicine in U.K.

The India’s pharmaceutical market is dominated by branded generics, creating generic-induced price competition. The robust growth of branded generics market in India also can be attributed to the rising disposable income, growing demand branded generics at low prices and increasing prevalence of chronic diseases.

Why is the U.S. anticipated to yield Credible Growth Opportunities?

In the U.S., the production of branded generics has increased substantially as they are less expensive than branded drugs and do not require extensive research and testing. Increasing prevalence of chronic diseases across the country such as cardiovascular diseases, diabetes, Alzheimer's diseases and Parkinson's diseases has provided the required thrust to the branded generics market.

Branded Generics Market - Category-wise Insights

Rising Prevalence of Cardiovascular Diseases Continue to Impacting the Branded Generics Market

Cardiovascular diseases (CVDs) and diabetes remain the top therapeutic application areas, accounting for more than increasing sales of branded generics in the global market.

According to World Health Organization (WHO), around 17.9 million people die each year from cardiovascular diseases (CVDs) around the world. Similarly, 1.13 billion people worldwide have hypertension. This leads to the adoption of branded generics such as anti-hypertensive drugs, which eventually expands Branded Generics Market.

Which Formulation Type Dominates the Branded Generics Market?

Oral formulation segment leads the Branded Generics Market with a share of more than 55%. The growth of the segment can be attributed to the convenience factor associated with oral administration.

Oral medications are easy to administer and patient compliance with oral medication is higher over other routes of administration. Moreover, tablets and capsules are being made more palatable using sweeteners and colored coatings.

However, FMI predicts that the parental formulation will take the spotlight during the forecast period. The parental segment is expected to take lead in the Branded Generics Market by 2031 end.

How are Online Pharmacies Contributing towards Branded Generics Sales?

In terms of distribution channel, Future Market Insights have segmented the Branded Generics Market into hospital pharmacies, retail pharmacies, online pharmacies and drug stores.

With the emergence of e-commerce, manufacturers are forging alliances with online and retail pharmacies. An unprecedented outbreak of COVID-19 normalized branded generics shopping via online pharmacies.

Patients find it easy and time-saving to directly get their medication from online pharmacies. As a result, online pharmacies are anticipated to gain traction through 2021 and beyond.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Branded Generics Market - Competitive Landscape

Key players operating in the Branded Generics Market are focusing on offering low-cost branded generics in order to gain a competitive edge in the market. For instance

  • In 2020 Mylan, a global pharmaceutical company announced the launch of its remdesivir under the brand name DESREM in India to address, unmet needs amid the evolving COVID-19 pandemic. The drug is approved for the treatment of suspected incidence of COVID-19 in adults and children with severe diseases symptoms.
  • In July 2021, Lupin announced that it will acquire Australia-based Southern Cross Pharma pvt Ltd (SCP).
  • In May 2021, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the launch of THIOLA (tiopronin) tablets for the presentation of cystine (kidney) stones.

Branded Generics Market - Scope of the Report

Attribute

Details

Forecast Period

2021-2031

Historical Data Available for

2016-2020

Market Analysis

USD Million for Value and ‘000 Units for Volume

Key Regions Covered

North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa

Key Countries Covered

US, Canada, Germany, U.K., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, and South Africa

Key Segments Covered

Therapeutic Application, Drug Class, Formulation Type, Distribution channel and Region.

Key Companies Profiled

Teva, Abbott Laboratories, Novartis, Mylan, Pfizer and others.

Report Coverage

Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Branded Generics Market by Category

Therapeutic Application:

  • Oncology
  • Cardiovascular Diseases
  • Diabetes
  • Neurology
  • Gastrointestinal Diseases
  • Dermatology Diseases
  • Analgesics and Anti-inflammatory
  • Others

Drug Class:

  • Alkylating Agents
  • Antimetabolites
  • Hormones
  • Anti-Hypertensive
  • Lipid Lowering Drugs
  • Anti-Depressants
  • Anti-Psychotics
  • Anti-Epileptics
  • Others

Formulation Type:

  • Oral
  • Parenteral
  • Topical
  • Others

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores

Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • MEA
  • Japan

Frequently Asked Questions

The branded generics market exceeded the total market value of US$ 283.2 Mn in 2021

The branded generics market exhibited steady growth at 6.5% CAGR between 2016 and 2020.

Entry of new branded generics, encouraging use of branded generics by healthcare providers and professionals and two-tiered strategy are some of the key trends driving the market.

Top prominent players of branded generics market are Teva, Abbott Laboratories, Novartis, Mylan and Pfizer

North America’s Branded Generics market demand is set to rise at 3.8% CAGR over the forecast period of 2021 and 2031.

Top players included in Tier-1 i.e., Pfizer Inc., Mylan N.V, Abbot Laboratories, Teva Pharmaceutical Industries Ltd. accounted for 20%-25% share in 2021.

Demand for branded generics is expected to register sluggish growth at 4.1% CAGR across Europe between 2021 and 2031.

The U.S., China, India, Russia and Brazil are the key producers of branded generics.

The key exporters of branded generics are China, India, Russia and the U.S.

Japan and South Korea accounts for 5% and 1% market share in 2021, respectively.

Table of Content

1. Executive Summary

    1.1. Market Outlook

    1.2. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Macro-Economic Factors

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity Analysis

        3.1.4. Trends

4. Market Context

    4.1. GlobalMarket: U.S. Regulation

    4.2. GlobalMarket: Europe Regulation

    4.3. GlobalMarket: Porter Five Forces Model

    4.4. GlobalMarket: Market Value Chain

5. GlobalMarket (in Value or Size in US$ Bn) Analysis 2016 - 2020 and Forecast, 2021 - 2031

    5.1. Historical Market Value (US$ Bn) Analysis, 2016 - 2020

    5.2. Current and Future Market Value (US$ Bn) Projections, 2021 - 2031

        5.2.1. Y-o-Y Growth Trend Analysis

        5.2.2. Absolute $ Opportunity Analysis

        5.2.3. Market Value Comparison

6. GlobalMarket Analysis 2016 - 2020 and Forecast 2021 - 2031, by Therapeutic Application

    6.1. Introduction / Key Findings

    6.2. Historical Market Size (US$ Bn) Analysis By Therapeutic Application, 2016 - 2020

    6.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Therapeutic Application, 2021 - 2031

        6.3.1. Oncology

        6.3.2. Cardiovascular Diseases

        6.3.3. Diabetes

        6.3.4. Neurology

        6.3.5. Gastrointestinal Diseases

        6.3.6. Dermatology Diseases

        6.3.7. Analgesics and Anti-inflammatory

        6.3.8. Others

    6.4. Market Attractiveness Analysis By Therapeutic Application

7. GlobalMarket Analysis 2016 - 2020 and Forecast 2021 - 2031, by Drug Class

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Bn) Analysis By Drug Class, 2016 - 2020

    7.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Drug Class, 2021 - 2031

        7.3.1. Alkylating Agents

        7.3.2. Antimetabolites

        7.3.3. Hormones

        7.3.4. Anti-Hypertensive

        7.3.5. Lipid Lowering Drugs

        7.3.6. Anti-Depressants

        7.3.7. Anti-Psychotics

        7.3.8. Anti-Epileptics

        7.3.9. Others

    7.4. Market Attractiveness Analysis By Drug Class

8. GlobalMarket Analysis 2016 - 2020 and Forecast 2021 - 2031, by Formulation Type

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Bn) Analysis By Formulation Type, 2016 - 2020

    8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast Formulation Type, 2021 - 2031

        8.3.1. Oral

        8.3.2. Parenteral

        8.3.3. Topical

        8.3.4. Others

        8.3.5. Others

9. GlobalMarket Analysis 2016 - 2020 and Forecast 2021 - 2031, by Distribution Channel

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Bn) Analysis By Distribution Channel, 2016 - 2020

    9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2021 - 2031

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

        9.3.4. Drug Stores

    9.4. Market Attractiveness Analysis By Distribution Channel

10. GlobalMarket Analysis 2016 - 2020 and Forecast 2021 - 2031, by Region Type

    10.1. Introduction

    10.2. Historical Market Size (US$ Bn) Analysis By Region, 2016 - 2020

    10.3. Current Market Size (US$ Bn) Analysis and Forecast By Region, 2021 - 2031

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Western Europe

        10.3.4. Eastern Europe

        10.3.5. Asia-Pacific Excluding Japan

        10.3.6. Japan

        10.3.7. Middle East and Africa

    10.4. Market Attractiveness Analysis By Region

11. North AmericaMarket Analysis 2016 - 2020 and Forecast 2021 - 2031

    11.1. Introduction

    11.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2016 - 2020

    11.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2021 - 2031

        11.3.1.  By Country

            11.3.1.1. U.S.

            11.3.1.2. Canada

        11.3.2. By Therapeutic Application

        11.3.3. By Drug Class

        11.3.4. By Formulation Type

        11.3.5. By Distribution Channel

    11.4. Market Attractiveness Analysis

        11.4.1. By Country

        11.4.2. By Therapeutic Application

        11.4.3. By Drug Class

        11.4.4. By Formulation Type

        11.4.5. By Distribution Channel

    11.5. Market Key Participants and Intensity Mapping

12. Latin AmericaMarket Analysis 2016 - 2020 and Forecast 2021 - 2031

    12.1. Introduction

    12.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2016 - 2020

    12.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2021 - 2031

        12.3.1.  By Country

            12.3.1.1. Mexico

            12.3.1.2. Brazil

            12.3.1.3. Rest of Latin America

        12.3.2. By Therapeutic Application

        12.3.3. By Drug Class

        12.3.4. By Formulation Type

        12.3.5. By Distribution Channel

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Therapeutic Application

        12.4.3. By Drug Class

        12.4.4. By Formulation Type

        12.4.5. By Distribution Channel

    12.5. Market Key Participants and Intensity Mapping

13. Western EuropeMarket Analysis 2016 - 2020 and Forecast 2021 - 2031

    13.1. Introduction

    13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2016 - 2020

    13.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2021 - 2031

        13.3.1.  By Country

            13.3.1.1. Germany

            13.3.1.2. Italy

            13.3.1.3. France

            13.3.1.4. U.K.

            13.3.1.5. Spain

            13.3.1.6. Nordics

            13.3.1.7. Rest of Western Europe

        13.3.2. By Therapeutic Application

        13.3.3. By Drug Class

        13.3.4. By Formulation Type

        13.3.5. By Distribution Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Therapeutic Application

        13.4.3. By Drug Class

        13.4.4. By Formulation Type

        13.4.5. By Distribution Channel

    13.5. Market Key Participants and Intensity Mapping

14. Eastern EuropeMarket Analysis 2016 - 2020 and Forecast 2021 - 2031

    14.1. Introduction

    14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2016 - 2020

    14.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2021 - 2031

        14.3.1.  By Country

            14.3.1.1. Russia

            14.3.1.2. Poland

            14.3.1.3. Rest of Eastern Europe

        14.3.2. By Therapeutic Application

        14.3.3. By Drug Class

        14.3.4. By Formulation Type

        14.3.5. By Distribution Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Therapeutic Application

        14.4.3. By Drug Class

        14.4.4. By Formulation Type

        14.4.5. By Distribution Channel

    14.5. Market Key Participants and Intensity Mapping

15. APEJMarket Analysis 2016 - 2020 and Forecast 2021 - 2031

    15.1. Introduction

    15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2016 - 2020

    15.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2021 - 2031

        15.3.1.  By Country

            15.3.1.1. China

            15.3.1.2. India

            15.3.1.3. Australia & New Zealand

            15.3.1.4. ASEAN

            15.3.1.5. Rest of APEJ

        15.3.2. By Therapeutic Application

        15.3.3. By Drug Class

        15.3.4. By Formulation Type

        15.3.5. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Therapeutic Application

        15.4.3. By Drug Class

        15.4.4. By Formulation Type

        15.4.5. By Distribution Channel

    15.5. Market Key Participants and Intensity Mapping

16. JapanMarket Analysis 2016 - 2020 and Forecast 2021 - 2031

    16.1. Introduction

    16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2016 - 2020

    16.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2021 - 2031

        16.3.1. By Therapeutic Application

        16.3.2. By Drug Class

        16.3.3. By Distribution Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Therapeutic Application

        16.4.2. By Drug Class

        16.4.3. By Formulation Type

        16.4.4. By Distribution Channel

    16.5. Market Key Participants and Intensity Mapping

17. Middle East and AfricaMarket Analysis 2016 - 2020 and Forecast 2021 - 2031

    17.1. Introduction

    17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2016 - 2020

    17.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2021 - 2031

        17.3.1. By Country

            17.3.1.1. GCC Countries

            17.3.1.2. South Africa

            17.3.1.3. Rest of MEA

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Therapeutic Application

        17.4.3. By Drug Class

        17.4.4. By Formulation Type

    17.5. Market Key Participants and Intensity Mapping

18. Competition Analysis and Covid-19 Impact

    18.1. Competition Dashboard

    18.2. Competition Deep Dive

        18.2.1. Pfizer Inc.

            18.2.1.1. Overview

            18.2.1.2. Product Portfolio

            18.2.1.3. Profitability by Market Segments (Product/Drug Class/Region)

            18.2.1.4. Sales Footprint

            18.2.1.5. Strategy Overview

                18.2.1.5.1. Marketing Strategy

                18.2.1.5.2. Product Strategy

                18.2.1.5.3. Drug Class Strategy

        18.2.2. Mylan N.V

            18.2.2.1. Overview

            18.2.2.2. Product Portfolio

            18.2.2.3. Profitability by Market Segments (Product/Drug Class/Region)

            18.2.2.4. Sales Footprint

            18.2.2.5. Strategy Overview

                18.2.2.5.1. Marketing Strategy

                18.2.2.5.2. Product Strategy

                18.2.2.5.3. Drug Class Strategy

        18.2.3. Abbott Laboratories

            18.2.3.1. Overview

            18.2.3.2. Product Portfolio

            18.2.3.3. Profitability by Market Segments (Product/Drug Class/Region)

            18.2.3.4. Sales Footprint

            18.2.3.5. Strategy Overview

                18.2.3.5.1. Marketing Strategy

                18.2.3.5.2. Product Strategy

                18.2.3.5.3. Drug Class Strategy

        18.2.4. Novartis AG

            18.2.4.1. Overview

            18.2.4.2. Product Portfolio

            18.2.4.3. Profitability by Market Segments (Product/Drug Class/Region)

            18.2.4.4. Sales Footprint

            18.2.4.5. Strategy Overview

                18.2.4.5.1. Marketing Strategy

                18.2.4.5.2. Product Strategy

                18.2.4.5.3. Drug Class Strategy

        18.2.5. Teva Pharmaceutical Industries Ltd

            18.2.5.1. Overview

            18.2.5.2. Product Portfolio

            18.2.5.3. Profitability by Market Segments (Product/Drug Class/Region)

            18.2.5.4. Sales Footprint

            18.2.5.5. Strategy Overview

                18.2.5.5.1. Marketing Strategy

                18.2.5.5.2. Product Strategy

                18.2.5.5.3. Drug Class Strategy

19. Assumptions and Acronyms Used

20. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Market Value (US$ Bn) Growth Comparison

Table 02: Global Market Value (US$ Bn) Analysis and Forecast 2021 - 2031, By Therapeutic Application

Table 03: Global Market Value (US$ Bn) Analysis and Forecast 2021 - 2031, By Drug Class

Table 04: Global Market Value (US$ Bn) Analysis and Forecast 2021 - 2031, By Type

Table 05: Global Market Value (US$ Bn) Analysis- and Forecast 2021 - 2031, By Distribution Channel

Table 06: Global Market Value (US$ Bn) Analysis and Forecast 2021 - 2031

Table 07: North America Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031By Therapeutic Application

Table 08: North America Market Value (US$ Bn) Analysis and Forecast 2021 - 2031, By Drug Class

Table 09: North America Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Formulation Type

Table 10: North America Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Distribution Channel

Table 11: North America Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Country

Table 12: Latin America Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Therapeutic Application

Table 13: Latin America Market Value (US$ Bn) Analysis and Opportunity Assessment 2016 - 2020, By Drug Class

Table 14: Latin America Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Formulation Type

Table 15: Latin America Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Distribution Channel

Table 16: Latin America Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Country

Table 17: Western Europe Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031Therapeutic Application

Table 18: Western Europe Market Value (US$ Bn) Analysis and Forecast 2021 - 2031, By Drug Class

Table 19: Western Europe Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Formulation Type

Table 20: Western Europe Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Distribution Channel

Table 21: Western Europe Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2019–2029, By Country

Table 22: Eastern Europe Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Therapeutic Application

Table 23: Eastern Europe Market Value (US$ Bn) Analysis and 2021 - 2031, By Drug Class

Table 24: Eastern Europe Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Formulation Type

Table 25: Eastern Europe Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Distribution Channel

Table 26: Eastern Europe Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Country

Table 27: APEJ Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Therapeutic Application

Table 28: APEJ Market Value (US$ Bn) Analysis and Opportunity Assessment 2021 - 2031, By Drug Class

Table 29: APEJ Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Formulation Type

Table 30: APEJ Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Distribution Channel

Table 31: APEJ Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Country

Table 32: Japan Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Therapeutic Application

Table 33: Japan Market Value (US$ Bn) Analysis and Opportunity Assessment 2021 - 2031, By Drug Class

Table 34: Japan Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Formulation Type

Table 35: Japan Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Distribution Channel

Table 36: Middle East & Africa Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Therapeutic Application

Table 37: Middle East & Africa Market Value (US$ Bn) Analysis and 2021 - 2031, By Drug Class

Table 38: Middle East & Africa Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031 By Formulation Type

Table 39: Middle East & Africa Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Distribution Channel

Table 40: Middle East & Africa Market Value (US$ Bn) Analysis 2016 - 2020 and Forecast 2021 - 2031, By Country

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Market Value Analysis (US$ Bn), 2016 - 2020

Figure 02: Global Market Value Forecast (US$ Bn), 2021 - 2031

Figure 03: Global Market Absolute $ Opportunity, 2021 - 2031

 Figure 04: Comparison Dec 17 and Dec 2019, Y-o-Y Forecast

Figure 05: Global Market Share Analysis (%), By Therapeutic Application, 2021 - 2031

Figure 06: Global Market Y-o-Y Analysis (%), By Therapeutic Application, 2021 - 2031

Figure 07: Global Market Attractiveness Analysis by Therapeutic Application, 2021 - 2031

Figure 08: Global Market Share Analysis (%), By Drug Class, 2021 - 2031

Figure 09: Global Market Y-o-Y Analysis (%), By Drug Class, 2021 - 2031

Figure 10: Global Market Attractiveness Analysis by Drug Class, 2021 - 2031

Figure 11: Global Market Share Analysis (%), By Formulation Type, 2021 - 2031

Figure 12: Global Market Y-o-Y Analysis (%), By Formulation Type, 2021 - 2031

Figure 13: Global Market Attractiveness Analysis by Formulation Type, 2021 - 2031

Figure 14: Global Market Share Analysis (%), By Distribution Channel, 2021 - 2031

Figure 15: Global Market Y-o-Y Analysis (%), By Distribution Channel, 2021 - 2031

Figure 16: Global Market Attractiveness Analysis by Distribution Channel, 2021 - 2031

Figure 17: Global Market Share Analysis (%), By Country, 2021 - 2031

Figure 18: Global Market Y-o-Y Analysis (%), By Country, 2021 - 2031

Figure 19: Global Market Attractiveness Analysis by Country, 2021 - 2031

Figure 20: North America Market Value Share By Therapeutic Application (2021)

Figure 21: North America Market Value Share By Drug Class (2021)

Figure 22: North America Market Value Share By Formulation Type (2021)

Figure 23: North America Market Value Share By Distribution Channel (2021)

Figure 24: North America Market Value Share By Country (2021)

Figure 25: North America Market Value Analysis (US$ Bn), 2016 - 2020

Figure 26: North America Market Value Forecast (US$ Bn), 2021 - 2031

Figure 27: North America Market Attractiveness Analysis by Therapeutic Application, 2021 - 2031

Figure 28: North America Market Attractiveness Analysis by Drug Class, 2021 - 2031

Figure 29: North America Market Attractiveness Analysis by Formulation Type, 2021 - 2031

Figure 30: North America Market Attractiveness Analysis by Distribution Channel, 2021 - 2031

Figure 31: North America Market Attractiveness Analysis by Country, 2021 - 2031

Figure 32: Latin America Market Value Share By Therapeutic Application (2021)

Figure 33: Latin America Market Value Share By Drug Class (2021)

Figure 34: Latin America Market Value Share By Formulation Type (2021)

Figure 35: Latin America Market Value Share By Distribution Channel (2021)

Figure 36: Latin America Market Value Share By Country (2021)

Figure 37: Latin America Market Value Analysis (US$ Bn), 2016 - 2020

Figure 38: Latin America Market Value Forecast (US$ Bn), 2021 - 2031

Figure 39: Latin America Market Attractiveness Analysis by Therapeutic Application, 2021 - 2031

Figure 40: Latin America Market Attractiveness Analysis by Drug Class, 2021 - 2031

Figure 41: Latin America Market Attractiveness Analysis by Formulation Type, 2021 - 2031

Figure 42: Latin America Market Attractiveness Analysis by Distribution Channel, 2021 - 2031

Figure 43: Latin America Market Attractiveness Analysis by Country, 2021 - 2031

Figure 44: Western Europe Market Value Share By Therapeutic Application (2021)

Figure 45: Western Europe Market Value Share By Drug Class (2021)

Figure 46: Western Europe Market Value Share By Formulation Type (2021)

Figure 47: Western Europe Market Value Share By Distribution Channel (2021)

Figure 48: Western Europe Market Value Share By Country (2021)

Figure 49: Western Europe Market Value Analysis (US$ Bn), 2016 - 2020

Figure 50: Western Europe Market Value Forecast (US$ Bn), 2021 - 2031

Figure 51: Western Europe Market Attractiveness Analysis by Therapeutic Application, 2021 - 2031

Figure 52: Western Europe Market Attractiveness Analysis by Drug Class, 2021 - 2031

Figure 53: Western Europe Market Attractiveness Analysis by Formulation Type, 2021 - 2031

Figure 54: Western Europe Market Attractiveness Analysis by Distribution Channel, 2021 - 2031

Figure 55: Western Europe Market Attractiveness Analysis by Country, 2021 - 2031

Figure 56: Eastern Europe Market Value Share By Therapeutic Application (2021)

Figure 57: Eastern Europe Market Value Share By Drug Class (2021)

Figure 58: Eastern Europe Market Value Share By Formulation Type (2021)

Figure 59: Eastern Europe Market Value Share By Distribution Channel (2021)

Figure 60: Eastern Europe Market Value Share By Country (2021)

Figure 61: Eastern Europe Market Value Analysis (US$ Bn), 2016 - 2020

Figure 62: Eastern Europe Market Value Forecast (US$ Bn), 2021 - 2031

Figure 63: Eastern Europe Market Attractiveness Analysis by Therapeutic Application, 2021 - 2031

Figure 64: Eastern Europe Market Attractiveness Analysis by Drug Class, 2021 - 2031

Figure 65: Eastern Europe Market Attractiveness Analysis by Formulation Type, 2021 - 2031

Figure 66: Eastern Europe Market Attractiveness Analysis by Distribution Channel, 2021 - 2031

Figure 67: Eastern Europe Market Attractiveness Analysis by Country, 2021 - 2031

Figure 68: APEJ Market Value Share By Therapeutic Application (2021)

Figure 69: APEJ Market Value Share By Drug Class (2021)

Figure 70: APEJ Market Value Share By Formulation Type (2021)

Figure 71: APEJ Market Value Share By Distribution Channel (2021)

Figure 72: APEJ Market Value Share By Country (2021)

Figure 73: APEJ Market Value Analysis (US$ Bn), 2016 - 2020

Figure 74: APEJ Market Value Forecast (US$ Bn), 2021 - 2031

Figure 75: APEJ Market Attractiveness Analysis by Therapeutic Application, 2021 - 2031

Figure 76: APEJ Market Attractiveness Analysis by Drug Class, 2021 - 2031

Figure 77: APEJ Market Attractiveness Analysis by Formulation Type, 2021 - 2031

Figure 78: APEJ Market Attractiveness Analysis by Distribution Channel, 2021 - 2031

Figure 79: APEJ Market Attractiveness Analysis by Country, 2021 - 2031

Figure 80: Japan Market Value Share By Therapeutic Application (2021)

Figure 81: Japan Market Value Share By Drug Class (2021)

Figure 82: Japan Market Value Share By Formulation Type (2021)

Figure 83: Japan Market Value Share By Distribution Channel (2021)

Figure 84: Japan Market Value (US$ Bn) & Forecast 2021 & 2031

Figure 85: Japan Market Value Analysis (US$ Bn), 2016 - 2020

Figure 86: Japan Market Value Forecast (US$ Bn), 2021 - 2031

Figure 87: Japan Market Attractiveness Analysis by Therapeutic Application, 2021 - 2031

Figure 88: Japan Market Attractiveness Analysis by Drug Class, 2021 - 2031

Figure 89: Japan Market Attractiveness Analysis by Formulation Type, 2021 - 2031

Figure 90: Japan Market Attractiveness Analysis by Distribution Channel, 2021 - 2031

Figure 91: Middle East & Africa Market Value Share By Therapeutic Application (2021)

Figure 92: Middle East & Africa Market Value Share By Drug Class (2021)

Figure 93: Middle East & Africa Market Value Share By Formulation Type (2021)

Figure 94: Middle East & Africa Market Value Share By Distribution Channel (2021)

Figure 95: Middle East & Africa Market Value Share By Country (2021)

Figure 96: Middle East & Africa Market Value Analysis (US$ Bn), 2016 - 2020

Figure 97: Middle East & Africa Market Value Forecast (US$ Bn), 2021 - 2031

Figure 98: Middle East & Africa Market Attractiveness Analysis by Therapeutic Application, 2021 - 2031

Figure 99: Middle East & Africa Market Attractiveness Analysis by Drug Class, 2021 - 2031

Figure 100: Middle East & Africa Market Attractiveness Analysis by Formulation Type, 2021 - 2031

Figure 101: Middle East & Africa Market Attractiveness Analysis by Distribution Channel, 2021 - 2031

Figure 102: Middle East & Africa Market Attractiveness Analysis by Country, 2021 - 2031

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Generic Injectable Market

Published : April 2021

Healthcare

Super Generics Market

Published : June 2017

Healthcare

Specialty Generics Market

Published : February 2017

Healthcare

Branded Generics Market

Published : August 2021

Google translate

Branded Generics Market